Abstract. hGRF (iv 50 \ g=m\ g) was administered to 6 normal young adult males at 09.00 and 20.00 h on different days. Nocturnal 
days. Nocturnal GH secretion was monitored during polygraphic sleep recordings on both control nights and nights following hGRF administration. Sleep-related GH secretion and sleep parameters were not affected by diurnal hGRF administration.
The close association in adult man between the occurrence of the initial episode of slow-wave sleep (SWS) and the highest peak of plasma GH concen¬ tration in a 24-h period led to the concept of sleep-related GH secretion (Takahashi et al. 1968; Sassin et al. 1969 ), submitted to control mecha¬ nisms probably different from those involved in day-time secretion and in pharmacologically indu¬ ced secretion (Mendelson et al. 1979 ).
It has been reported that in man administration of GH subsequently can blunt the secretory re¬ sponse to pharmacological stimulation of GH secretion (Hagen et al. 1972 ) as well as sleeprelated GH secretion (Mendelson et al. 1983 ). This negative feedback appears, then, to be exerted at some common point of the pathways involved in the secretory mechanisms.
Administration of GH in animals (Stern et (Mendelson et al. 1980; Mendelson 1982) , whereas iterative administration has no significant effect on sleep (Mendelson et al. 1983 ). Synthetic human growth hormone-releasing fac¬ tor (hGRF) powerfully stimulates GH release in normal young adult men (Thorner et al. 1983; Rosenthal et al. 1983; Gelato et al. 1984; Sassolas et al. 1984) . This study was undertaken in order to determine whether a GH-rise, induced during day¬ time by hGRF administration, would exert an effect on the sleep-related GH secretion and on sleep stages.
Materials and Methods
Six normal young men (22-26 years of age) taking no medication, within 10% of their ideal body weights, were enrolled for this study. They had given written informed consent. Protocol had been approved by our institutional Ethics Committee.
The subjects were admitted to the Centre de Médecine Nucléaire (Lyon) for two trial periods at intervals of 1 week. The first period included a first control night (CNl) , iv administration of 50 pg hGRF at 09.00 h (mGRF) and the subsequent night (mGRF-N). The second period also included a control night (CN2), iv administration of 50 pg hGRF at 20.00 h (eGRF) and the following night (eGRF-N) (Fig. 1 10,20,30,40,50,60,90, 120, 150, 180 min. GH determinations were performed in duplicate, as previously described (Sassolas et al. 1984 3) Study of GH secretion during sleep (sleep-AUC) during the first 3 h (lst3h-AUC), and during the 1st and 2nd sleep cycles (1st cycle-AUC aiid 2nd cycle-AUC) revealed no significant difference between the control and the post-hGRF nights (Table 1) . 4) Moreover, the first nocturnal peak of GH secretion was not significantly modified by recent hGRF injections either at the time of occurrence or in the latency related to sleep onset (ANOVA). Mean sleep characteristics in the 6 subjects during control nights (CN1 and CN2) and experimental nights after morning and evening iv injection of 50 pg GRF, respectively, (mGRF-N and eGRF-N). Our study also shows that the response to hGRF does not differ significantly when the injection is given in the morning and in the evening. These results are in accordance with those of Takano et al. (1984) in normal subjets of small stature in whom injections were administered in the morning and 2 h after lunch. However, they differ from those obtained by Nathan et al. ( 1979) showing GH responses to insulin-induced hypoglycaemia to depend on injection time.
Our (Mendelson et al. 1983) , and of the GH response to GRF (Rosenthal et al. 1984) 
